4D Molecular Therapeutics

FDMTNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$841.922 M

$15.24 +0.13%

Close of 21 Sept 2026

Revenue

$85.2M

#2559 by revenue

Earnings

-$140.1M

Loss-making

Shares outstanding

55,214,097

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#54Electra TherapeuticsETRA$895.8M
#55Candel TherapeuticsCADL$857.8M
#564D Molecular TherapeuticsFDMT$841.9M
#57DBV TechnologiesDBVT$716.1M
#58Aura BiosciencesAURA$659.6M

What if 4D Molecular Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$548,004.10

Per share 35,958× higher

Bitcoin $1.72T

$31,130.93

Per share 2,043× higher

Nvidia $5.48T

$99,193.34

Per share 6,509× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for 4D Molecular Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.